Your browser doesn't support javascript.
loading
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.
Jurczak, Wojciech; Rule, Simon; Townsend, William; Tucker, David; Sarholz, Barbara; Scheele, Jürgen; Dyroff, Martin; Gribben, John G; Dlugosz-Danecka, Monika; Zinzani, Pier Luigi.
Afiliação
  • Jurczak W; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
  • Rule S; Department of Haematology, Plymouth University Medical School, Plymouth, UK.
  • Townsend W; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Tucker D; NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.
  • Sarholz B; Department of Haematology, Royal Cornwall Hospitals NHS Trust, Truro, UK.
  • Scheele J; R&D Global Biostatistics & Epidemiology, Merck KGaA, Darmstadt, Germany.
  • Dyroff M; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA (an affiliate of Merck KGaA, Darmstadt, Germany).
  • Gribben JG; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA (an affiliate of Merck KGaA, Darmstadt, Germany).
  • Dlugosz-Danecka M; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Zinzani PL; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Leuk Lymphoma ; 62(10): 2392-2399, 2021 10.
Article em En | MEDLINE | ID: mdl-33896333

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article